Disc Medicine Grants Amgen Option to Acquire for $1.4B
Ticker: IRON · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1816736
| Field | Detail |
|---|---|
| Company | Disc Medicine, Inc. (IRON) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition-option, collaboration, biotech
TL;DR
Amgen has option to buy Disc Medicine for up to $1.4B, deal announced April 1st.
AI Summary
Disc Medicine, Inc. announced on April 1, 2024, that it has entered into a strategic collaboration and license agreement with Amgen Inc. This agreement grants Amgen an exclusive option to acquire Disc Medicine for a potential total consideration of up to $1.4 billion, including an upfront payment and potential milestone payments. The collaboration focuses on Disc Medicine's portfolio of therapies targeting complement-mediated diseases.
Why It Matters
This significant deal could lead to a substantial acquisition for Disc Medicine shareholders and represents a major validation of their complement-mediated disease therapies by a large pharmaceutical company like Amgen.
Risk Assessment
Risk Level: medium — The deal is contingent on Amgen exercising its option and achieving certain milestones, introducing uncertainty about the final acquisition price and timeline.
Key Numbers
- $1.4B — Potential Acquisition Value (Maximum potential consideration Amgen could pay to acquire Disc Medicine.)
Key Players & Entities
- Disc Medicine, Inc. (company) — Registrant
- Amgen Inc. (company) — Collaborator and potential acquirer
- $1.4 billion (dollar_amount) — Potential total consideration for acquisition
- April 1, 2024 (date) — Date of earliest event reported
- Gemini Therapeutics, Inc. (company) — Former company name
- FS Development Corp. (company) — Former company name
FAQ
What is the nature of the agreement between Disc Medicine and Amgen?
Disc Medicine entered into a strategic collaboration and license agreement with Amgen Inc., granting Amgen an exclusive option to acquire Disc Medicine.
What is the maximum potential value of the acquisition by Amgen?
The potential total consideration for the acquisition could be up to $1.4 billion, including an upfront payment and potential milestone payments.
What is the effective date of the reported event?
The date of the earliest event reported is April 1, 2024.
What is the primary focus of the collaboration between Disc Medicine and Amgen?
The collaboration focuses on Disc Medicine's portfolio of therapies targeting complement-mediated diseases.
What were Disc Medicine's previous company names?
Disc Medicine was formerly known as Gemini Therapeutics, Inc. and FS Development Corp.
Filing Stats: 1,575 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2024-04-02 17:25:57
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma
Filing Documents
- d815786d8k.htm (8-K) — 38KB
- d815786dex991.htm (EX-99.1) — 23KB
- g815786g36x65.jpg (GRAPHIC) — 27KB
- 0001193125-24-084937.txt ( ) — 233KB
- iron-20240401.xsd (EX-101.SCH) — 3KB
- iron-20240401_lab.xml (EX-101.LAB) — 18KB
- iron-20240401_pre.xml (EX-101.PRE) — 11KB
- d815786d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Disc Medicine, Inc. on April 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: April 2, 2024 By: /s/ John Quisel Name: John Quisel, J.D. Ph.D. Title: Chief Executive Officer